paywalled: (BMN-673) Promise for BRCA-defective cancers : Nature Reviews Cancer

Nature Reviews Cancer

Nature Reviews Cancer

13,

439

(2013)

doi:10.1038/nrc3552

Published online

24 June 2013

"Germline mutations of either BRCA1 or BRAC2 are particularly associated with an increased risk for breast and ovarian cancer. The initial results of a Phase I/II trial reported at the annual meeting of the American Society of Clinical Oncology indicate that a new drug, BMN-673, developed by BioMarin Pharmaceuticals in…"